TCM
REGN icon

Triumph Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Triumph Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
414
+35
+9% +$23.8K 0.05% 323
2026
Q1 		$293K Buy
379
+18
+5% +$13.8K 0.06% 274
2025
Q4 		$279K Sell
361
-104
-22% -$70.6K 0.06% 262
2025
Q3 		$262K Sell
465
-378
-45% -$214K 0.07% 269
2025
Q2 		$443K Buy
843
+251
+42% +$140K 0.13% 176
2025
Q1 		$375K Buy
592
+32
+6% +$22K 0.13% 183
2024
Q4 		$399K Buy
560
+137
+32% +$115K 0.14% 182
2024
Q3 		$445K Buy
+423
New +$471K 0.16% 146

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Triumph Capital Management's REGN Position: Q2 2026 in Review

Triumph Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 9.2% in Q2 2026, buying an estimated $23.8K and bringing the position to 414 shares worth $258K. The position accounts for 0.05% of the portfolio, ranked #323.

Triumph Capital Management first reported a position in REGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $445K in Q3 2024. 240 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Triumph Capital Management held 414 shares of Regeneron Pharmaceuticals worth $258K as of Q2 2026.
  • Triumph Capital Management bought 35 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $23.8K.
  • Regeneron Pharmaceuticals made up 0.05% of Triumph Capital Management's portfolio in Q2 2026, its #323 holding.
  • Triumph Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Triumph Capital Management's Regeneron Pharmaceuticals position peaked at $445K in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.